Mutation-induced changes in binding free energy (ΔΔG) at antibody–antigen interfaces are important for antibody optimization, mutational scanning, and viral immune escape assessment. However, computational prediction remains challenging because antibodies and antigens have distinct sequence backgrounds, mutation effects are often localized at interfaces, and related complexes may remain across training and evaluation partitions. We present AbAgMut-GNN as a task-oriented paired graph framework that coordinates established sequence and geometric learning components around explicit comparison of wild-type (WT) and mutant (MUT) antibody–antigen complexes. AntiBERTy and ESM2 provide frozen residue-level embeddings for antibody and antigen chains, respectively, while mutation-centered, interface-aware, paired-residue, and contact-delta representations capture local perturbations and interaction remodeling. We evaluate AbAgMut-GNN under four complementary internal settings, including the PDB-based split, the complex-cluster split, the antibody-family preserving validation split, and the antigen-cluster-preserving validation split. Under the complex-cluster split, AbAgMut-GNN achieves Pearson correlation coefficients of 0.5841 on AB-Bind and 0.5480 on SKEMPI v2.0. External validation on SARS-CoV-2 and influenza antibody–antigen systems further shows useful mutation-effect correlation trends, although absolute-error performance varies across target systems. Contact-masking and residue-class enrichment analyses indicate that model-derived importance patterns are associated with biologically relevant interface interactions. Overall, AbAgMut-GNN is best viewed as a task-oriented computational tool for trend-level mutation ranking and pre-experimental candidate prioritization rather than as a high-precision substitute for quantitative biophysical measurement.
Wenchi Ge, Qi-Jia Yu, Jincen Shuai et al.· Journal of Chemical Informat...· 0 citations
Drug combination therapy plays an increasingly important role in the clinical treatment of complex diseases, such as cancer, as rational drug combinations can enhance therapeutic efficacy and reduce toxic side effects. However, existing methods still exhibit limitations in the granularity of drug molecular representation, drug interaction modeling, and cell line context awareness, which restrict further improvements in predictive performance. To address these issues, we propose FragSyn, a deep graph learning framework for predicting synergistic drug combinations based on molecular fragmentations. FragSyn first decomposes drug molecules into chemically meaningful fragments according to breaks of retrosynthetically interesting chemical substructure rules and learns fragment-level molecular representations through a graph isomorphism network with edge features. It then captures nonlinear relationships between drug pairs from multiple perspectives while introducing a gating modulation mechanism conditioned on cell line features, enabling drug representations to adapt dynamically to the cell line context. Finally, multisource features are fused to perform binary classification of synergy versus antagonism. FragSyn achieves AUC, AUPR, and ACC of 0.944, 0.942, and 0.872, respectively, outperforming eight baseline models, and demonstrates optimal generalization performance in both leave-one-out cross-validation and external validation. Ablation studies and interpretability analyses further validate the rationality of FragSyn and its ability to identify key fragments. These results indicate that FragSyn, through the synergistic design of fragment-level representation and cellular context awareness, provides an effective and interpretable new approach to synergistic drug combination prediction.
Lifeng Shao, Jianqiang Sun, Hong-Zhan Ma et al.· Journal of Chemical Informat...· 0 citations
This review elucidates the paradigm shift in drug discovery from serendipitous exploration to rational, structure-driven polypharmacological molecular engineering, thereby providing a clear, structured guide for navigating the complexities of next-generation therapeutics.
Tianming Han, Zhijie Pan, Wenchi Ge et al.· 0 citations